CN102488740A - Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen - Google Patents
Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen Download PDFInfo
- Publication number
- CN102488740A CN102488740A CN2011104143496A CN201110414349A CN102488740A CN 102488740 A CN102488740 A CN 102488740A CN 2011104143496 A CN2011104143496 A CN 2011104143496A CN 201110414349 A CN201110414349 A CN 201110414349A CN 102488740 A CN102488740 A CN 102488740A
- Authority
- CN
- China
- Prior art keywords
- bean sprout
- extract
- rat
- estrogen
- isoflavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of chickpea sprout extracts in medicines for preventing deficiency of estrogen. The chickpea sprout extracts are chickpea sprout isoflavone extracts, are used as estrogen receptor regulator, and are used for preparing medicines and health care products which are used for preventing or treating climacteric syndrome and osteoporosis. Tests show that the chickpea sprout isoflavone extracts can directly act onto the uterus of a patient, can remarkably increase estradiol level in blood serum, have regulating and controlling effects to a hypothalamus-hypophysis- neuroendocrine system, remarkably increase thighbone density and relative bone volume of an SD (Sprague Dawley) rat without the ovary, increase the thickness of bone trabecula, reduce separating degree of the bone trabecula, decrease the quantity of osteoclast, can alleviate bone loss of the thighbone of the rat due to the fact that the ovary of the rat is removed, increase bearing capacity of the thighbone, play an important role in regulating internal secretion conditions of middle-aged and elderly women after menopause, improving menopause symptoms such as hot flash, palpitate, skin dryness and the like and reducing possibility of osteoporosis, and lay a foundation in industrial development of functional factors of chickpeas.
Description
Technical field:
The present invention relates to the purposes of a kind of olecranon bean sprout extract at the medicine of preventing and treating estrogen loss, particularly a kind of olecranon bean sprout isoflavone extract is in preparation prevention and the climacteric syndrome of treatment estrogen loss and the purposes of osteoporosis Chinese medicine.
Background technology:
Climacteric syndrome be middle aged and aged women owing to ovarian function fails gradually, estrogen level descends gradually back companion come comprise symptoms such as hectic fever, cardiopalmus, xerosis cutis, urine urgency-frequency, sore waist and aching in the waist and the back, closely related with the estrogen level rapid drawdown.Osteoporosis then is another common disease that middle aged and aged women body inner estrogen level descends and caused; Mainly be that it is active and uneven to cause bone metabolism because the agonism of the estrogen receptor that decrease in estrogen causes existing in the osseous tissue weakens, the osteoblast activity is suppressed and the osteoclast activity strengthens; Cause bone formation not enough; Bone resorption is hyperfunction, shows as bone density and descends symptoms such as bone Biomass reduction.In recent years the middle aged and aged women investigation of health conditions is found that climacteric syndrome and osteoporosis have become influence the climacteric women primary factor of healthy and quality of life.How to improve climacteric women health status and quality of life through adjustment climacteric women body inner estrogen level, be an urgent demand of society and middle aged and aged women self.
Phytoestrogen is one type of natural origin, can combines, bring into play the plant extract of weak estrogen action with estrogen receptor, has the two-ways regulation function of estrogen-like.Phytoestrogen mainly is divided into osajin, coumestrol and lignin three major types.Isoflavone is as wherein important one type; Discovered in recent years its for estrogen associated cancer, climacteric syndrome, cardiovascular diseases, osteoporosis, early senile dementia disease has prevention and therapeutical effect preferably, can effectively avoid synthetic estrogen such as Reynolds west is fragrant, tamoxifen causes carcinoma of endometrium and breast carcinoma.Present domestic report several plant such as isoflavone extracts such as Radix Puerariae, Radix Ginseng have the phytoestrogen function.
Chickpea (Semen Ciceris Ari ni) is a leguminous plant, because of its seed point like olecranon, so a chickpea.The extensive cultivating and growing in Xinjiang.In Central Asia, chickpea is not only a kind of important food, also is a kind of traditional Uygur medicine medicinal herbs most in use simultaneously, has invigorating the spleen and replenishing QI, warming the kidney to invigorate YANG, mainly quenches one's thirst, separates face poison, skin care, bone strengthening, is good for the stomach, effect such as nourishing the lung to arrest cough.Be used for the prevention and the treatment of diseases such as the tired sexual impotence of body, soreness of waist and knee joint, inappetence, empty, the diabetes of body and lung abscess be swollen after being ill.Modern pharmacological research proves that chickpea contains particular chemical composition and significant biological activity, is a kind of Chinese crude drug with extensive pharmacologically active, and the activity of having reported has:
Blood sugar lowering: chickpea 70% ethanol extraction and water extract divide low (5g/kg), in (10g/kg), high (20g/kg) 3 dose groups give mouse stomach 14 days, can obviously reduce the mouse blood sugar activity.Infer with its saponin chemical constituent relevant.
Resisting fatigue: after adopting water extract method to extract the chickpea polysaccharide; According to irritating stomach 25d according to group and basic, normal, high three the variable concentrations dose groups of chickpea polysaccharide; Carry out swimming with a load attached to the body test respectively, and superoxide dismutase (Superoxide Dismutase SOD) activity, malonaldehyde (Maleic Dialdehyde MDA) content and the muscle glycogen of its serum and liver, hepatic glycogen, serum urea nitrogen, blood lactate level etc. are tested.Result of study demonstration chickpea polysaccharide can prolong the swimming with a load attached to the body time of mice, and the SOD that strengthens mice serum and liver is active, reduces MDA content, improves hepatic glycogen, muscle glycogen storage level, serum urea and blood lactate level behind the reduction mouse movement.The result shows chickpea polysaccharide tool obvious anti-fatigue function.
Anticancer: as to discover that the crude flavonoid powder material that extracts in the chickpea can significantly suppress stomach cancer cell MGC-9 multiplication capacity.In addition; The olecranon bean peptide is organized the mouse stomach administration of giving subcutaneous vaccination hepatocarcinoma H22 cell respectively with low 50mg/kgd, middle 100mg/kgd, high dose group 200mg/kgd; Result of study shows that three dosage all can suppress the H22 growth of tumor, and does not hinder the growth of mice body weight and immune organ.Compare with the tumor matched group; The chickpea high dose group can significantly improve ability, lymphocyte and the macrophage phagocytic ability (P＜0.05) of mice delayed hypersensitivity (DTH); Low, the middle dose groups of chickpea also has some improvement to it, but does not show dose-dependent effect.
Blood fat reducing: with chickpea low dose group (10g/kg/d); Chickpea high dose group (20g/kg/d); The olecranon Semen Glycines powder is mixed with normal diet, feed mice after 12 days, measure its fasting glucose, serum cholesterol (Tc), triglyceride (TG) content; The result shows that chickpea has good blood sugar lowering and effect for reducing blood fat to the hyperglycemia mice, has positive effect to prevent diabetes and complication thereof.
The prevention senile dementia: the Chickpea isoflavone extract hang down 25mg/kgd, middle 50mg/kgd, high dose group 100mg/kgd can significantly improve the SOD activity that the D-galactose causes the cerebral tissue of aging model mouse model; Reduce the MDA level; Improve the mouse aging cerebral tissue and remove the ability of free radical; Reduce the peroxidating product to brain tissue injury, and then improve the degree of brain aging, bring into play its anti-aging effects.
Antiviral: Biochanin A shows the research of HIV HIV-1 activity and CD lymphocyte early activation function influence: it is active and suppress the effect of CD lymphocyte early activation that Biochanin A has that anti-HIV-1 cell fusion mediated and HIV-1 duplicate.
Up to the present, also do not see both at home and abroad about the estrogenic activity of olecranon bean sprout isoflavone extract with as the report of estrogenic agents in treatment middle aged and aged women climacteric syndrome or prevention of osteoporosis.
Summary of the invention:
The object of the invention is; The purposes of a kind of olecranon bean sprout extract at the medicine of preventing and treating estrogen loss is provided; This olecranon bean sprout isoflavone extract is as medicine and the purposes of health product of estrogenic agents in preparation prevention or treatment climacteric syndrome and osteoporosis, for the industry development of chickpea functional factor lays the foundation.
A kind of olecranon of the present invention bean sprout extract is in the purposes of the medicine of preventing and treating estrogen loss, and this olecranon bean sprout extract is the purposes of the medicine of olecranon bean sprout isoflavone extract in the climacteric syndrome of preparation prevention and treatment estrogen loss.
The purposes of the health product of this olecranon bean sprout isoflavone extract in the climacteric syndrome of preparation prevention estrogen loss.
The purposes of this olecranon bean sprout isoflavone extract in the osteoporosis agents of preparation prevention and treatment estrogen loss.
The purposes of this olecranon bean sprout isoflavone extract in the osteoporosis health product of preparation prevention estrogen loss.
A kind of olecranon of the present invention bean sprout extract is in the purposes of the medicine of preventing and treating estrogen loss; Wherein olecranon bean sprout extract is the Chickpea isoflavone extract, through patent of invention 201010614623.X chickpea bean sprout valid part and its production and application in obtain.It is alcohol extracting method or water extraction preparation that this effective site adopts solvent extraction method, and concrete operations follow these steps to carry out:
A, chickpea is also dry with the conventional method germination pulverizes, and crosses 25 mesh sieves;
B, with adding 2-10 times of methanol or ethanol or isopropyl alcohol or the butanols that volumetric concentration is 10-100% in the powder of exsiccant chickpea bean sprout, with ultrasound wave or merceration or heating and refluxing extraction 1-15 time, 1-3 hour at every turn; Filter; Merging filtrate, being evaporated to does not have the alcohol flavor, obtains ethanol extract; Wherein the ultrasonic extraction temperature is 20-40 ℃, and the reflux, extract, temperature is 60-80 ℃;
C or with the pure water that adds 2-10 times of volume in fresh chickpea bean sprout or the exsiccant chickpea bean sprout powder; With ultrasound wave or merceration or heating and refluxing extraction 1-15 time, each 2-4 hour, filter; Merging filtrate; Concentrating under reduced pressure obtains water extract, and wherein the ultrasonic extraction temperature is 20-60 ℃, and the reflux, extract, temperature is 60-100 ℃;
D, with the water extract of the ethanol extract of step b or step c with containing crude drug amount 0.04g/mL, as the upper prop test liquid, the upper prop test liquid is admixed in the polyamide powder; Use water elution, the polyamide behind the water elution is placed FL-3 macroporous resin top, again with concentration 10%-100% ethanol elution; Collect eluent; Merge, concentrate, can obtain chickpea bean sprout valid part total saponins class, osajin;
E, be standard substance with oleanolic acid and Biochanin A respectively with effective site total saponins and isoflavone levels again, use determined by ultraviolet spectrophotometry.
The olecranon bean sprout isoflavone extract that the present invention obtains patent of invention 201010614623.X has carried out the research of the purposes of prevention and treatment climacteric syndrome and osteoporosis Chinese medicine or health product, is based on experiment and clinical research is accomplished.Observe olecranon bean sprout isoflavone extract estrogen and bone photo in the adult female rats developing womb of OO SD, the serum are closed index.The result shows that the olecranon bean sprout middle and high dosage of isoflavone extract has obviously improved the uterus weight in wet base, has increased body of gland quantity in endometrium thickness and the inner membrance basic unit, shows the uterus estrogen-like effects.In addition; Olecranon bean sprout isoflavone extract can significantly improve the secretion situation of gonadal hormone in the serum; Improved the concentration of 17-β estradiol in the serum; FSH and LH secretion level have been reduced simultaneously; Show that olecranon bean sprout isoflavone extract possibly have certain regulating and controlling effect to hypothalamus-hypophysis-neuroendocrine system, prompting olecranon bean sprout isoflavone extract has great importance for menopause syndrome such as regulating the relevant hectic fever of postclimacteric endocrine situation of middle aged and aged women and improvement and FSH, LH, cardiopalmus, xerosis cutis.The influence of bone metabolism discovered that the remarkable bone density improving of olecranon bean sprout isoflavone extract and the relative bone volume of middle high dose have increased bone trabecula thickness; Reduce clearence degree between the bone trabecula, and reduced amount of osteoclast, reduced the bone suction; Prompting olecranon bean sprout isoflavone extract can be alleviated the rat bone loss that removal ovary causes; Increase the bone bearing capacity, reduce the bone resorption of osteoclast, prevention of osteoporosis is had positive role.
Description of drawings
Fig. 1 is rat uterus immunohistochemical analysis tectology figure of the present invention (sham operated rats), the expression of black arrow indication inner membrance specific mark albumen PCNA (PCNA), and figure is 100 times of amplifications.
Fig. 2 is rat uterus immunohistochemical analysis tectology figure of the present invention (model group), the expression of black arrow indication inner membrance specific mark albumen PCNA (PCNA), and figure is 100 times of amplifications.
Fig. 3 is rat uterus immunohistochemical analysis tectology figure of the present invention (estradiol group),, the expression of black arrow indication inner membrance specific mark albumen PCNA (PCNA), figure is 100 times of amplifications.
Fig. 4 is rat uterus immunohistochemical analysis tectology figure of the present invention (olecranon bean sprout extract high dose group), and black arrow indication inner membrance specific mark albumen PCNA (PCNA) is expressed, and figure is 100 times of amplifications.
Fig. 5 is rat uterus immunohistochemical analysis tectology figure of the present invention (sham operated rats), and brown area is the expression of progesterone receptor (PR), and figure is 100 times of amplifications.
Fig. 6 is rat uterus immunohistochemical analysis tectology figure of the present invention (model group), and brown area is the expression of progesterone receptor (PR), and figure is 100 times of amplifications.
Fig. 7 is rat uterus immunohistochemical analysis tectology figure of the present invention (estradiol group), and brown area is the expression of progesterone receptor (PR), and figure is 100 times of amplifications.
Fig. 8 is rat uterus immunohistochemical analysis tectology figure of the present invention (olecranon bean sprout extract high dose group), and brown area is the expression of progesterone receptor (PR), and figure is 100 times of amplifications.
The specific embodiment
Embodiment 1 (purposes of olecranon bean sprout isoflavone extract in the medicine of the climacteric syndrome of preparation prevention and treatment women estrogen loss)
Olecranon bean sprout isoflavone extract is to the influence of female sd inbred rats uterus and estrogen level:
Receive the reagent thing: estradiol valerate (Estradiol Valerate), (Guangzhou) pharmaceutcal corporation, Ltd of spirit earlier produces, and lot number (J20080036) is processed suspension with Semen Maydis oil.The Chickpea isoflavone extract is accomplished through the following step by this laboratory:
A, chickpea is also dry with the conventional method germination pulverizes, and crosses 25 mesh sieves;
B, with adding 2-10 times of methanol or ethanol or isopropyl alcohol or the butanols that volumetric concentration is 10-100% in the powder of exsiccant chickpea bean sprout, with ultrasound wave or merceration or heating and refluxing extraction 1-15 time, 1-3 hour at every turn; Filter; Merging filtrate, being evaporated to does not have the alcohol flavor, obtains ethanol extract; Wherein the ultrasonic extraction temperature is 20-40 ℃, and the reflux, extract, temperature is 60-80 ℃;
C or with the pure water that adds 2-10 times of volume in fresh chickpea bean sprout or the exsiccant chickpea bean sprout powder; With ultrasound wave or merceration or heating and refluxing extraction 1-15 time, each 2-4 hour, filter; Merging filtrate; Concentrating under reduced pressure obtains water extract, and wherein the ultrasonic extraction temperature is 20-60 ℃, and the reflux, extract, temperature is 60-100 ℃;
D, with the water extract of the ethanol extract of step b or step c with containing crude drug amount 0.04g/mL, as the upper prop test liquid, the upper prop test liquid is admixed in the polyamide powder; Use water elution, the polyamide behind the water elution is placed FL-3 macroporous resin top, again with concentration 10%-100% ethanol elution; Collect eluent; Merge, concentrate, can obtain chickpea bean sprout valid part total saponins class, osajin;
E, be standard substance with oleanolic acid and Biochanin A respectively with effective site total saponins and isoflavone levels again, use determined by ultraviolet spectrophotometry.
The isoflavone content 73.36% that obtains through this method calculates and uses by the estrogenic amount of contained natural plants wherein, is made into variable concentrations solution respectively, and all medicines are prepared by Semen Maydis oil, and temperature stores for future use for 4 ℃.
Animal subject: ten age in week SD female secondary rat, purchase in Xinjiang Endemic Disease Prevention and Cure Inst.'s Experimental Animal Center (quality certification number: 20110222), body weight 220 (± 10g).Divide sham operated rats, model group, estradiol group, olecranon bean sprout isoflavone extract low dose group, middle dose groups and high dose group, 8 every group.
Modeling: except that sham operated rats, all the other each group is cut abdominal part open from the rat ventrimeson, extracts bilateral ovaries, operation stitching then, and the rat repeat surgery step of sham operated rats, but do not extract ovary.
Medication: after the operation, each organizes 2 weeks of rat normal diet, the beginning administration of the 3rd week of operation back; Continued for 5 weeks; Normal group, model group and sham operated rats are irritated stomach with the Semen Maydis oil of administration group equal volume every day, and the estradiol group is irritated stomach every day and given estradiol 0.25mg/ (kg.day); Olecranon bean sprout isoflavone extract low dose group is irritated stomach 200mg/ (kg.day); Dose groups in the isoflavone extract of olecranon bean sprout is irritated stomach 500mg/ (kg.day); Olecranon bean sprout isoflavone extract high dose group is irritated stomach 1000mg/ (kg.day).
Index observing:
1) the uterus weight in wet base is observed: each organizes the back anesthesia of 5 week of administration, cuts off the abdomen median line, with the uterus with peel off fully on every side, weigh.
2) immunohistochemical analysis: fresh uterine cancer cell is with the fixing back preparation of the formalin solution of 10% PBS preparation paraffin section, with the expression of HE dyeing and SABC method tissues observed form and differential protein pS2 and PR.
3) hormone determination: each organizes the back anesthesia of 5 week of administration, lumbar injection, and abdominal aortic blood, separation of serum, one 20 ℃ of storages, the employing radioimmunoassay method is surveyed estradiol (E2) in the serum, short follicle generates plain (FSH) and interstitialcellstimulating hormone (ICSH) (LH) content.
Data statistics is handled: data all with means standard deviation (means ± s) expression, statistical procedures is checked with t, P＜0.05 is a significant difference, P＜0.01 is that difference is extremely remarkable.
Experimental result
Olecranon bean sprout isoflavone extract is to the influence of SD rat uterus weight:
The influence that table 1 olecranon bean sprout isoflavone extract is grown the removal ovary rat uterus (means ± s, n=8)
Annotate: compare ##p＜0.01, #p＜0.05 with sham operated rats; Compare * * p＜0.01 with model group, * p＜0.05.
The result is as shown in table 1: after bilateral ovaries excised for 7 weeks, and the obvious atrophy of rat uterus, model group is compared with sham operated rats, and uterus weight significantly reduces (P＜0.01).After 5 weeks of administration, dose groups, high dose group can make the uterus of atrophy recover (P＜0.05) to some extent in the isoflavone extract of olecranon bean sprout, and olecranon bean sprout isoflavone extract low dose group does not have remarkable effect.
Olecranon bean sprout isoflavone extract is to the influence of SD rat uterus tissue morphology:
The caliber of normal uterus is thick, the intrauterine thickness, the inner membrance abundant glandular (Fig. 1, Fig. 5); After the spay, SD rat uterus internal diameter and narrow, endometrial cell attenuation; The inner membrance body of gland reduces (Fig. 2; Fig. 6), after the isoflavone extract treatment of olecranon bean sprout was fed in filling, the uterus internal diameter enlarged than model group to some extent; (Fig. 1-Fig. 8), olecranon bean sprout isoflavone extract high dose group is superior to low dose group to the expression indication intimal epithelium cell body of gland epithelial cell proliferation situation of inner membrance specific mark albumen PCNA (PCNA) and progesterone receptor (PR).
Olecranon bean sprout isoflavone extract is to the influence of estrogen level in the SD rat blood serum:
Table 2 olecranon bean sprout isoflavone extract to the influence of removal ovary rat blood serum hormonal readiness (means ± s, n=8)
Annotate: compare ##p＜0.01, #p＜0.05 with sham operated rats; Compare * * p＜0.01 with model group, * p＜0.05
The result is as shown in table 2: after the rat ovary excision, the estradiol level in the serum obviously reduces, and model group is compared significant difference (P＜0.01) with sham operated rats; Simultaneously follicle stimulating hormone (FSH) and metakentrin (LH) level significantly raise (P＜0.01); Estradiol can recover female estrogen level in the serum after handling, and behind the olecranon bean sprout isoflavone extract extract of dosage and high dose, estrogen level is identical with estradiol processed group trend in the serum in the gastric infusion; Show as estradiol level significantly raise (P＜0.01); FSH and LH significantly reduce, FSH (P＜0.05), LH (P＜0.01).
Conclusion:
Rat uterus mensuration biology is the classical way of research medicine estrogen vigor always; In above-mentioned experiment; The SD rat oral gavage that the olecranon bean sprout isoflavone extract of dosage and high dose is given removal ovary in the use is after 5 weeks; Can significantly increase SD rat uterus weight, increase body of gland quantity in endometrium thickness and the inner membrance basic unit, show the uterus estrogen-like effects; In addition, olecranon bean sprout isoflavone extract can significantly improve the secretion situation of estrogen in the serum, and the olecranon bean sprout isoflavone extract of dosage and high dose can directly act on the uterus in showing as, and significantly improves estradiol level in the serum; And on the other hand; In the olecranon bean sprout isoflavone extract of high dose can resist the FSH that causes owing to decrease in estrogen after the oophorectomize and the raising of LH level; Show that olecranon bean sprout isoflavone extract possibly have regulating and controlling effect to hypothalamus-hypophysis-neuroendocrine system, this has great importance for menopause syndrome such as regulating the relevant hectic fever of postclimacteric endocrine situation of middle aged and aged women and improvement and FSH, LH, cardiopalmus, xerosis cutis.
Experimental example 2 (purposes of chickpea bean sprout isoflavone extract in the medicine of the osteoporosis of prevention and treatment estrogen loss)
Olecranon bean sprout isoflavone extract is to the bone protective effect of removal ovary SD rat:
Receive the reagent thing: estradiol valerate (Estradiol Valerate), (Guangzhou) pharmaceutcal corporation, Ltd of spirit earlier produces lot number (J20080036); Process suspension with Semen Maydis oil, identical among Chickpea isoflavone extract and the embodiment 1, wherein isoflavone content 73.36%; Calculate and use by the estrogenic amount of contained natural plants wherein; Be made into variable concentrations solution respectively, all medicines are prepared by Semen Maydis oil, and temperature stores for future use for 4 ℃.
Animal subject: ten age in week SD female secondary rat, purchase in Xinjiang Endemic Disease Prevention and Cure Inst.'s Experimental Animal Center (quality certification number: 20110222), body weight 220 (± 10g).Divide sham operated rats, model group, estradiol group, olecranon bean sprout isoflavone extract low dose group, middle dose groups and high dose group, 8 every group.
Modeling: except that sham operated rats, all the other each groups are cut abdominal part open from the rat ventrimeson, extract bilateral ovaries, operation stitching then.The rat repeat surgery step of sham operated rats, but do not extract ovary.
Medication: after the operation, each organizes 2 weeks of rat normal diet, and the beginning administration of the 3rd week of operation back continued for 5 weeks; Normal group, model group and sham operated rats are irritated stomach with administration group equal volume Semen Maydis oil every day; The estradiol group is irritated stomach every day and is given estradiol 0.25mg/ (kg.day); Olecranon bean sprout isoflavone extract low dose group is irritated stomach 200mg/ (kg.day); Dose groups in the isoflavone extract of olecranon bean sprout is irritated stomach 500mg/ (kg.day); Olecranon bean sprout isoflavone extract high dose group is irritated stomach 1000mg/ (kg.day).
Index observing:
Irritate stomach after 5 weeks, anesthesia is cut off the abdomen median line, abdominal aortic blood 5ml; 800 rev/mins centrifugal 10 minutes, separation of serum is peeled off rat left and right side femur, the muscle that will adhere to and fascia are rejected clean; Immerse immediately in the formalin solution, 4 ℃ of preservations of temperature, observe following index:
1) measurement of indexs such as relative bone volume, bone density, bone trabecula thickness and bone trabecula separating degree:
From formalin solution, take out the right side femur during measurement; Dry its attaching liq; Use toy Micro-CT system scan system to scanning, measure bone density (BMD), relative bone volume (BV/TV), bone trabecula thickness (Tb.th), bone trabecula separating degree indexs such as (Tb.sp).
2) osseous tissue morphological analysis:
Take out the right side femur of dipped into formalin; Through with 10% sodium ethylene diamine tetracetate (EDTA) solution decalcification of phosphate buffer (PBS) preparation after 20 days; With the fixing back of neutral formalin paraffin section, with the quantity of osteoclast in HE dyeing and SABC method tissues observed form and the unit of analysis area.
Data statistics is handled:
Data represent with means standard deviation that all statistical procedures is checked with t, and P＜0.05 is a significant difference, and P＜0.01 is that difference is extremely remarkable.
Experimental result
Table 3 olecranon bean sprout isoflavone extract to removal ovary rat bone morphosis parameter influence (means ± s, n=8)
Annotate: compare ##p＜0.01, #p＜0.05 with sham operated rats; Compare * * p＜0.01 with model group, * p＜0.05
The result is visible by table 3,1) after the SD rat is extractd ovary, femoral bmd, relative bone volume, with Sham-operated control group than significantly reducing (P＜0.05), the modeling success; After high dose olecranon bean sprout isoflavone extract is irritated stomach, can significantly improve the relative bone volume and the bone density of removal ovary rat femur.2) the bone trabecula thickness of removal ovary rat femur is compared remarkable reduction (P＜0.05) with sham operated rats, the bone trabecula separating degree significantly increases (P＜0.05); Middle dosage and high dose olecranon bean sprout isoflavone extract increase bone trabecula thickness (P＜0.05), have reduced the bone trabecula separating degree, significant difference (P＜0.05).3) osteoclast in the removal ovary rat bone cavity is compared remarkable increase (P＜0.05) with sham operated rats, middle dosage and high dose olecranon bean sprout isoflavone extract have significantly reduced the quantity (P＜0.05) of osteoclast in the unit are.
Conclusion:
Removal ovary (OVX) rat is the animal model of the simulation women's osteosporosis after menopause disease generally acknowledged of U.S. FDA, and this specific character has been imitated the osteoporotic bone loss state of high conversion type after the normal menopause of people preferably.Therefore, with this model olecranon bean sprout isoflavone extract is estimated as osteoporosis therapy medicine and scheme.
In experiment of the present invention, rat bone density in the model group (BMD) and bone photo all significantly reduce volume (BV/TV), the bone trabecula attenuation, and the gap increases between the bone trabecula, shows the osteoporosis symptom.The olecranon bean sprout isoflavone extract of middle dosage and high dose group has significantly increased femur density and the relative bone volume of OO SD rat; Increased bone trabecula thickness; Reduce separating degree between the bone trabecula, and reduced amount of osteoclast, reduced bone resorption.This prompting olecranon bean sprout isoflavone extract can be alleviated the bone loss of the rat femur that removal ovary causes, has increased the bearing capacity of femur, has reduced the bone resorption of osteoclast, for osteoporosis positive effect takes place to have.
Claims (4)
1. an olecranon bean sprout extract is characterized in that in the purposes of the medicine of preventing and treating estrogen loss this olecranon bean sprout extract is the purposes of the medicine of olecranon bean sprout isoflavone extract in the climacteric syndrome of preparation prevention and treatment estrogen loss.
2. purposes according to claim 1 is characterized in that the purposes of the health product of this olecranon bean sprout isoflavone extract in the climacteric syndrome of preparation prevention estrogen loss.
3. purposes according to claim 1 is characterized in that the purposes of this olecranon bean sprout isoflavone extract in the osteoporosis agents of preparation prevention and treatment estrogen loss.
4. purposes according to claim 1 is characterized in that the purposes of this olecranon bean sprout isoflavone extract in the osteoporosis health product of preparation prevention estrogen loss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104143496A CN102488740A (en) | 2011-12-13 | 2011-12-13 | Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104143496A CN102488740A (en) | 2011-12-13 | 2011-12-13 | Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102488740A true CN102488740A (en) | 2012-06-13 |
Family
ID=46180643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104143496A Pending CN102488740A (en) | 2011-12-13 | 2011-12-13 | Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102488740A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547002A (en) * | 2015-02-15 | 2015-04-29 | 中国科学院新疆理化技术研究所 | Anti-inflammation application of chick-pea sprout extract |
| CN105031019A (en) * | 2015-09-14 | 2015-11-11 | 中国科学院新疆理化技术研究所 | Compound medicine for treating female postmenopausal osteoporosis and preparation method |
| CN106615132A (en) * | 2016-11-28 | 2017-05-10 | 山东坤泰生物科技有限公司 | Formulated milk drink capable of improving osteoporosis and preparation method of formulated milk drink |
| CN110227074A (en) * | 2019-06-25 | 2019-09-13 | 泰山医学院 | Protective effect of the Biochanin A to Hippocampal Neuron Cells |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947251A (en) * | 2010-09-21 | 2011-01-19 | 东华大学 | Method for preparing chickpea isoflavone microcapsules |
| CN102068486A (en) * | 2010-12-30 | 2011-05-25 | 中国科学院新疆理化技术研究所 | Effective fractions of cicer arietinum linn bean sprout and preparation method and application thereof |
-
2011
- 2011-12-13 CN CN2011104143496A patent/CN102488740A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101947251A (en) * | 2010-09-21 | 2011-01-19 | 东华大学 | Method for preparing chickpea isoflavone microcapsules |
| CN102068486A (en) * | 2010-12-30 | 2011-05-25 | 中国科学院新疆理化技术研究所 | Effective fractions of cicer arietinum linn bean sprout and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 田春元: "鹰嘴豆生药学的初步研究", 《安徽农业科学》, vol. 37, no. 18, 20 June 2009 (2009-06-20), pages 8464 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547002A (en) * | 2015-02-15 | 2015-04-29 | 中国科学院新疆理化技术研究所 | Anti-inflammation application of chick-pea sprout extract |
| CN105031019A (en) * | 2015-09-14 | 2015-11-11 | 中国科学院新疆理化技术研究所 | Compound medicine for treating female postmenopausal osteoporosis and preparation method |
| CN106615132A (en) * | 2016-11-28 | 2017-05-10 | 山东坤泰生物科技有限公司 | Formulated milk drink capable of improving osteoporosis and preparation method of formulated milk drink |
| CN110227074A (en) * | 2019-06-25 | 2019-09-13 | 泰山医学院 | Protective effect of the Biochanin A to Hippocampal Neuron Cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7763284B2 (en) | Method for treating or preventing symptoms associated with menopause | |
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| KR101794836B1 (en) | A composition of angelicae gigantis radix, cnidii rhizoma and cinnamomi cortex for treating menopause and partial androgen deficiency in aging male | |
| CN101002847A (en) | Medicine for treating mazoplasia, and its preparing method | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN105920086A (en) | Preparation method of fructus psoraleae extract and fructus psoraleae extract | |
| CN102488740A (en) | Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen | |
| CN103690782B (en) | A kind of Chinese medicine composition, preparation method and quality determining method for the treatment of climacteric syndrome | |
| US20180353559A1 (en) | Composition for preventing and treating climacteric disorder containing extracts of dendropanax morbifera lev. as active ingredient | |
| CN103461540B (en) | Functional fat with effect of preventing disease of prostate and preparation method thereof | |
| CN101138597B (en) | Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same | |
| CN102356876B (en) | Health food for preventing and treating premature aging of women and preparation method thereof | |
| CN101618087B (en) | Health-care food with function of improving climacteric | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN107412510B (en) | A kind of Chinese medicine composition with tonifying both YIN and YANG effect and preparation method thereof | |
| CN104173858A (en) | Danefukang granules and preparation method thereof | |
| CN101128210B (en) | A herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis | |
| CN102961415B (en) | Phellinus lonicericola or the purposes of its extract | |
| CN105250556A (en) | Traditional Chinese medicine drug for treating polycystic ovarian syndrome | |
| CN102048841A (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN103330721A (en) | Holothurian flower extract for treatment of female POF and its preparation method | |
| CN107198727A (en) | A kind of pharmaceutical composition of beautifying face and moistering lotion promoting blood circulation for regulating menstruation and preparation method thereof | |
| CN103919961B (en) | Middle and old age kidney-jing deficiency and kidney yang deficiency treatment traditional Chinese medicine preparation and preparation method thereof | |
| CN101574498B (en) | Compound cornu cervi pantotrichum bone strengthening capsule for treating osteoporosis and method for quatitatively determining the quality thereof | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120613 |